- Details
- Robert Reiter and Phillip Koo discuss his lecture on oligometastatic disease at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Reiter highlights next-generation imaging and its impact on managing patients with oligometastatic disease. Biographies: Robert E. Reiter, MD, MBA, the Bing Professor of Urologic Oncology and Director of UCLA's prostate cancer program, Director of Urol...
|
- Details
- A more common but often less talked about negative side effect of androgen deprivation therapy is the presence of hot flushes in men. In this discussion with Carmel Pezaro, Mark Frydenberg highlights solutions to this issue ranging from simple everyday adaptations to investigating alternative complementary therapies and drugs. Biographies: Mark Frydenberg, MD, Vice President, President-elect, Urol...
|
- Details
- Declan Murphy sits down with Alicia Morgans during the Advanced Prostate Cancer Consensus Conference (APCCC 2019) to discuss men who have node positive but nonmetastatic prostate cancer and how we think about approaching treatment and integrating new imaging modalities into that entire therapeutic paradigm. Two aspects of managing node positive men in regards to surgery were talked about including...
|
- Details
- Alberto Bossi presented on the recommended treatment for men with pathological node-positive prostate cancer. These patients are becoming more common as surgery is being performed on a higher proportion of high-risk patients with positive nodes. Highlighting unanswered questions regarding the treatment of these patients following surgery, Dr. Alberto Bossi mentions several studies that have assess...
|
- Details
- As a follow-up to Dr. Stefano Fanti’s presentation on the advantages of PSMA PET-CT imaging, Dr. Ian Davis from Melbourne discussed some of the pitfalls and disadvantages of PSMA PET-CT in advanced prostate cancer imaging. Biography: Professor Ian Davis, MB, BS, Ph.D., FRAC,P FAChPM, is a medical oncologist, cancer immunologist, clinician-scientist, and NHMRC Practitioner Fellow. He is Professor o...
|
- Details
- In this conversation with Charles Ryan, MD, Mack Roach III, MD discusses radiotherapy options for patients with clinically node-positive prostate cancer. In particularly with oligometastatic disease we are seeing long-term follow-up from a number of trials and have begun integrating data from these trials into clinical practice. Biographies: Mack Roach III, MD, Professor of Radiation Oncology and...
|
- Details
- In this conversation with Charles Ryan, Mark Rubin highlights the key points he addresses in his 2019 Advanced Prostate Cancer Consensus Conference presentation where he speaks about the future of biomarkers in advanced prostate cancer. Biographies: Mark A. Rubin, MD, Professor, Principal Investigator, and Director Department for BioMedical Research (DBMR), University of Bern, Switzerland. Dr. Rub...
|
- Details
- Mack Roach presents on radiotherapy options for patients with clinically node-positive prostate cancer at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Dr. Roach touches on areas such as the optimal candidate for salvage lymph node dissection (SLND) for nodal recurrence of prostate cancer, the role of adding ADT to radiotherapy, and the NRG/RTOG 9413 study which showed whole pelv...
|
- Details
- Karim Fizazi summarizes how best to treat node-positive (cN+) prostate cancer patients at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). There are over 20 randomized controlled trials in localized and advanced prostate cancer that have been published according to Dr. Fizazi, yet he notes, none have been published in the setting of node-positive prostate cancer. In this presentatio...
|
- Details
- Christopher Logothetis presents on the ethnicity and prognosis of prostate cancer during the Regional Care (Demographic and Environmental Factors) Session at the Advanced Prostate Cancer Consensus Conference the (APCCC 2019). Dr. Logothetis discusses the significant difference in the incidence and mortality of prostate cancer worldwide. There are greater differences in the incidence rates than in...
|
